Please login to the form below

Not currently logged in

Purdue Pharma appoints Dr Alan Dunton

He joins the pain specialist as senior VP of research and development

Purdue Pharma Dr Alan DuntonPurdue Pharma has appointed Dr Alan Dunton as senior vice president of research and development in a role that also sees him join its executive committee.

Dr Dunton will serve as the company's lead scientist and oversee medical research, drug safety, clinical pharmacology, virtual discovery, project management, and pharmaceutics and analytics teams.

He will report to chief executive officer Mark Timney who said: "At a time of transformation for Purdue, Alan brings the right skills and

experience to diversify and grow our portfolio."

Dr Dunton has spent 33 years in the industry discovering and developing new prescription and over-the-counter products. In 2006, he

founded Danerius, a biotechnology and pharmaceutical consulting business, which he led until joining Purdue. 

Prior to starting Danerius, Dr. Dunton held executive-level positions in the pharmaceutical and biotechnology industries, including President and Chief Executive Officer of Panacos Pharmaceuticals and Metaphore Pharmaceuticals.

He was also the president and managing director of the Janssen Research Foundation, the R&D arm of the pharmaceuticals division at Johnson & Johnson.

7th December 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Grace Communications

Grace Communications is a creative agency specialising in healthcare communication and understanding people's personality types....

Latest intelligence

Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...